# آشنایی با Pubmed

فاطمه صادقی غیاثی

مرکز پزشکی مبتنی بر شواهد


National Library of Medicine
National Center for Biotechnology Information
Log in
PubMed.gov
Search PubMed
Search
Advanced
PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books.
Citations may include links to full-text content from PubMed Central and publisher web sites.
Feedback

# سوال

آیا **پلاسما** در **درمان** **بیماری کرونا** نقش مؤثری دارد؟

# PICO

**P (Problem/Patient):** Covid-19 ; coronavirus disease 2019 ; SARS-CoV-2 ; ……

**I (Intervention):** Plasma ; convalescent plasma ; plasma transfusion ; CPT ; …..

**C (Comparison):** ---------

**O (Outcome):** Treatment ; Therapy ; ……..

# روش اول


PubMed.gov
covid-19 and plasma
Search
Advanced
PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books.
Citations may include links to full-text content from PubMed Central and publisher web sites.

National Library of Medicine
National Center for Biotechnology Information

PubMed.gov

covid-19 and plasma

Search

Advanced Create alert Create RSS User Guide

Save Email Send to Sorted by: Best match Display options

MY NCBI FILTERS

824 results

RESULTS BY YEAR


TEXT AVAILABILITY

- Abstract
- Free full text

1 Deployment of convalescent **plasma** for the prevention and treatment of **COVID-19**.

Cite Share

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA.

J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.

PMID: 32254064 Free article. Review.

**Severe acute respiratory syndrome coronavirus 2** (**SARS-CoV-2**), the cause of **coronavirus** disease **2019** (**COVID-19**), has spurred a global health crisis. To date, there are no proven options for ...

2 Collecting and evaluating convalescent **plasma** for **COVID-19** treatment: why and how?

# روش دوم


PubMed.gov
(covid-19 or coronavirus or SARS-CoV-2) and (Plasma or convalescent plasma or CPT)
Search
Advanced
PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books.
Citations may include links to full-text content from PubMed Central and publisher web sites.

PubMed.gov

9 or coronavirus or SARS-CoV-2) and (Plasma or convalescent plasma or CPT)

Search

Advanced Create alert Create RSS User Guide

Save Email Send to Sorted by: Best match Display options

MY NCBI FILTERS

1,170 results

RESULTS BY YEAR




TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

ARTICLE ATTRIBUTE

Did you mean *(covid-19* ***or coronavirusfor*** *SARS-CoV-2) and (****plasma or convalescent plasma for cpt****)* (824 results)?

1 Cite Share

## Collecting and evaluating **convalescent plasma** for **COVID-19** treatment: why and how?

Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y.

Vox Sang. 2020 Apr 2. doi: 10.1111/vox.12926. Online ahead of print.

PMID: 32240545 Review.

**Plasma** provided by **COVID-19 convalescent** patients may provide therapeutic relief as the number of **COVID-19** cases escalates steeply worldwide. ...Identifying, collecting, qualifying and preparing **plasma** from **convalescent** pati ...

2 Cite

## Deployment of **convalescent plasma** for the prevention and treatment of **COVID-19**.

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ,

# Advanced Search




PubMed Advanced Search Builder
PubMed.gov
User Guide
انتخاب یکی از عملگرهای بولین برای ترکیب کلیدواژه ها
Add terms to the query box
All Fields
Enter a search term
ADD
Add with AND
Add with OR
Add with NOT
Publication Type
Publisher
Secondary Source ID
Subject - Personal Name
Supplementary Concept
Text Word
Title
Title/Abstract
Transliterated Title
Volume
انتخاب فیلد جستجوی کلیدواژه
you use PubMed your recent searches will appear here.


PubMed Advanced Search Builder
PubMed.gov
User Guide
Add terms to the query box
All Fields
Enter a search term
ADD
Show Index
جستجو و نمایش نتایج جستجو
Query box
Enter / edit your search query here
Search
Add to History


Query box
Enter / edit your search query here
Add to History
اضافه کردن استراتژی و نتایج جستجو
در باکس history

Add terms to the query box

Title/Abstract

Enter a search term

ADD

Show Index

Query box

Enter / edit your search query here

Add to History

## History and Search Details

Download Delete

| Search | Actions | Details | Query | Results | Time |
|---|---|---|---|---|---|
| #1 | ••• | › | Search: **((((covid-19) OR (coronavirus 2019)) OR (SARS-CoV-2))) AND (plasma[Title/Abstract])** | 807 | 09:55:19 |


Query box
((((covid-19) OR (coronavirus 2019)) OR (SARS-CoV-2))) AND (plasma[Title/Abstract])
Add to History
History and Search Details
Download
Delete
Search
Actions
Details
Query
Results
Time
#1
((covid-19) OR (coronavirus 2019)) OR (SARS-CoV-2))) AND Title/Abstract])
807
09:55:19
Add with AND
Add with OR
Add with NOT
Delete
Create alert
Showing 1 to 1 of 1
Blog
Support Center

# نتایج جستجو

PubMed.gov

(covid-19 or coronavirus 2019 or SARS-Cov-2) and plasma

Search

Advanced Create alert Create RSS User Guide

Save Email Send to Sorted by: Best match Display options

MY NCBI FILTERS

833 results

RESULTS BY YEAR




TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

ARTICLE ATTRIBUTE

1 Cite Share

Antibody responses to **SARS-CoV-2** in patients of novel **coronavirus** disease **2019**.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z.

Clin Infect Dis. 2020 Mar 28:ciaa344. doi: 10.1093/cid/ciaa344. Online ahead of print.

PMID: 32221519 Free PMC article.

METHODS: A total of 173 patients with **SARS-CoV-2** infection were enrolled. Their serial **plasma** samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against **SARS-CoV-2**. ...CONCLUSION ...

2 Cite Share

Inhibition of **SARS-CoV-2** (previously **2019-nCoV**) infection by a highly potent pan-**coronavirus** fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L.

Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.


Save
Email
Send to
Sorted by: Best match
Display options
833 results
Save citations to file
Selection:
All results on this page
Format:
Summary (text)
Summary (text)
PubMed
PMID
Abstract (text)
CSV
Cre
833 results

Save | Email | Send to | Sorted by: Best match | Display options

833 results

## Email citations

Subject: (covid-19 or coronavirus 2019 or SARS-Cov-2) and - PubMed

To: email@example.com

Selection: **All results on this page**

Format: **Summary**

I'm not a robot

reCAPTCHA
Privacy - Terms

**Send email** | Cancel


Save
Email
Send to
Sorted by: Best match
Display options
833 results
Save
Email
Send to
Sorted by: Best
Clipboard
My Bibliography
Collections
Citation manager
Cancel
Create a file for external citation management software
Selection:
All results
Create file
Cancel

Save | Email | Send to | Sorted by: Best match | Display options

833 results



Clin Infect Dis. 2020 Mar 28;ciaa344. doi: 10.1093/cid/ciaa344. Online ahead of print.

# Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Juanjuan Zhao [1], Quan Yuan [2 3], Haiyan Wang [1], Wei Liu [2 3], Xuejiao Liao [1], Yingying Su [2 3], Xin Wang [1], Jing Yuan [4], Tingdong Li [2 3], Jinxiu Li [5], Shen Qian [1], Congming Hong [2 3], Fuxiang Wang [4], Yingxia Liu [4 6], Zhaoqin Wang [6], Qing He [6], Zhiyong Li [3], Bin He [2 3], Tianying Zhang [2 3], Yang Fu [7], Shengxiang Ge [2 3], Lei Liu [1 6], Jun Zhang [2 3], Ningshao Xia [2 3], Zheng Zhang [1 6]

Affiliations + expand

PMID: 32221519 PMCID: PMC7184337 DOI: 10.1093/cid/ciaa344

Free PMC article

## Abstract

**Background:** The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.

**Methods:** A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed.

**Results:** Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then

# فیلترها

RESULTS BY YEAR




TEXT AVAILABILITY

- [ ] Abstract
- [ ] Free full text
- [ ] Full text

ARTICLE ATTRIBUTE

- [ ] Associated data

ARTICLE TYPE

- [ ] Books and Documents
- [ ] Clinical Trial
- [ ] Meta-Analysis
- [ ] Randomized Controlled Trial
- [ ] Review
- [ ] Systematic Review



# فیلترها


Additional filters
Reset all filt
ARTICLE TYPE
SPECIES
LANGUAGE
SEX
SUBJECT
JOURNAL
AGE
Address
Autobiography
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Study
Clinical Trial Protocol
Clinical Trial, Phase I
Journal Article
Lecture
Legal Case
Legislation
Letter
Multicenter Study
News
Newspaper Article
Observational Study
Observational Study, Veterinary
Cancel
Show

Review > Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.

# Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design

Paul Barone [1], Robert A DeSimone [1]

Affiliations + expand

PMID: 32374891 PMCID: PMC7267607 DOI: 10.1111/trf.15843

Free PMC article

PREV RESULT
3 of 833

NEXT RESULT
5 of 833

## Abstract

Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for severe illness. Previous studies of convalescent plasma in treating other viral diseases have identified factors to consider when designing treatment protocols, including timing of administration relative to onset of illness, timing of donation relative to resolution of symptoms, severity of illness of the donor, pretransfusion serology of the recipient, and antibody titers of the donor. There are many clinical trials studying treatment of, and prophylaxis against, COVID-19 using convalescent plasma. In addition to clinical trials, the FDA also allows treatment through two other pathways: the "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19" protocol, and emergency investigational new drug applications. The FDA also provides criteria for donation of convalescent plasma.

Review > Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.

# Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design

Paul Barone [1], Robert A DeSimone [1]

Affiliations + expand

PMID: 32374891 PMCID: PMC7267607 DOI: 10.1111/trf.15843

Free PMC article

PREV RESULT
3 of 833

NEXT RESULT
5 of 833

FULL TEXT LINKS

WILEY Full Text Article

PMC FREE Full text

ACTIONS

Cite

Favorites

SHARE

PAGE NAVIGATION

Title & authors

Abstract

Conflict of interest statement

## Abstract

Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for severe illness. Previous studies of convalescent plasma in treating other viral diseases have identified factors to consider when designing treatment protocols, including timing of administration relative to onset of illness, timing of donation relative to resolution of symptoms, severity of illness of the donor, pretransfusion serology of the recipient, and antibody titers of the donor. There are many clinical trials studying treatment of, and prophylaxis against, COVID-19 using convalescent plasma. In addition to clinical trials, the FDA also allows treatment through two other pathways: the "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19" protocol, and emergency investigational new drug applications. The FDA also provides criteria for donation of convalescent plasma.

# Cite


CITATION TEXT
Barone, P., & DeSimone, R. A. (2020). Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. *Transfusion*, *60*(6), 1123–1127. https://doi.org/10.1111/trf.15843
Copy
Download .nbib
Format: APA

# Page Navigation

## Supplementary concepts

> COVID-19
> severe acute respiratory syndrome coronavirus

## Related information

MedGen

## LinkOut – more resources

**Full Text Sources**

Europe PubMed Central
Ovid Technologies, Inc.
PubMed Central
Wiley

**Medical**

MedlinePlus Health Information

PAGE NAVIGATION

## MeSH terms

- Antibodies, Viral / blood*
- Betacoronavirus / immunology*
- Blood Component Transfusion / methods*
- Clinical Trials as Topic / methods*
- Convalescence*
- Coronavirus Infections / immunology
- Coronavirus Infections / therapy*
- Coronavirus Infections / virology
- Humans
- Pandemics
- Plasma / immunology*
- Pneumonia, Viral / immunology
- Pneumonia, Viral / therapy*
- Pneumonia, Viral / virology
- Research Design

## Substances

- Antibodies, Viral